Reuters: Regulatory News: UPDATE 1-Globeimmune files for $69 mln IPO

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

UPDATE 1-Globeimmune files for $69 mln IPO Jul 2nd 2012, 22:19 Mon Jul 2, 2012 6:19pm EDT July 2 (Reuters) - Biopharmaceutical company Globeimmune Inc filed with regulators to raise up to $69 million in an initial public offering of its common shares. Wells Fargo Securities, Piper Jaffray and JMP Securities are underwriting the IPO, Globeimmune said in a filing with the U.S. Securities and Exchange Commission. Globeimmune, which is partially owned by a unit of biotechnology company Celgene Corp, said it has filed an application for its common stock to be listed on the Nasdaq under the symbol "GBIM." The Louisville, Colorado based-company has a strategic collaboration with Celgene for all cancer-related treatments, and with Gilead Sciences Inc for chronic hepatitis B virus. The filing did not reveal the number of shares the company plans to sell or their expected price. The amount of money a company says it plans to raise in its first IPO filings is used to calculate registration fees. The final size of the IPO could be different.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions